Yishai Ofran

Hematology And Stem Cell Transplantation Department And The Eisenberg RD Authority
Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 103 publications

Author Correction: The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Author Correction: The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Journal: Nature communications

Published: June 11, 2026

Is CPX-351 the best path to remission for older patients with treatment-related or myelodysplastic-related acute myeloid leukemia?

Is CPX-351 the best path to remission for older patients with treatment-related or myelodysplastic-related acute myeloid leukemia?

Journal: Haematologica

Published: May 12, 2026

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Journal: EJHaem

Published: March 19, 2026

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Journal: Annals of hematology

Published: January 29, 2026

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Journal: Annals of hematology

Published: January 29, 2026

Lnk Governs chemokine-directed trafficking of CD8+ T cells in melanoma.

Lnk Governs chemokine-directed trafficking of CD8+ T cells in melanoma.

Journal: Molecular therapy. Oncology

Published: December 16, 2025

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Journal: Blood neoplasia

Published: October 06, 2025

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Journal: Blood

Published: September 16, 2025

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

Journal: Blood

Published: September 16, 2025

HiDAC Consolidation in AML: Comparable Outcomes With Reduced Toxicity Using a Three-Day Schedule (HiDAC-123).

HiDAC Consolidation in AML: Comparable Outcomes With Reduced Toxicity Using a Three-Day Schedule (HiDAC-123).

Journal: European journal of haematology

Published: March 11, 2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Journal: Blood advances

Published: February 24, 2025

Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature.

Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature.

Journal: Acta haematologica

Published: January 04, 2025

Showing 1-12 of 103

Last Updated: 09/26/2026